Supernus Pharmaceuticals, Inc.

NasdaqGM:SUPN 주식 보고서

시가총액: US$1.5b

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Supernus Pharmaceuticals 관리

관리 기준 확인 2/4

Supernus Pharmaceuticals' CEO는 Jack Khattar, Jan2005 에 임명되었습니다 의 임기는 19.42 년입니다. 총 연간 보상은 $ 13.28M, 7.3% 로 구성됩니다. 7.3% 급여 및 92.7% 보너스(회사 주식 및 옵션 포함). 는 $ 51.66M 가치에 해당하는 회사 주식의 3.52% 직접 소유합니다. 51.66M. 경영진과 이사회의 평균 재임 기간은 각각 9.2 년과 14.4 년입니다.

주요 정보

Jack Khattar

최고 경영자

US$13.3m

총 보상

CEO 급여 비율7.3%
CEO 임기19.6yrs
CEO 소유권3.5%
경영진 평균 재임 기간9.3yrs
이사회 평균 재임 기간14.6yrs

최근 관리 업데이트

Recent updates

Supernus Pharmaceuticals: So-So Neuroscience Portfolio, With ADHD Standout

Jul 02

Subdued Growth No Barrier To Supernus Pharmaceuticals, Inc.'s (NASDAQ:SUPN) Price

Apr 24
Subdued Growth No Barrier To Supernus Pharmaceuticals, Inc.'s (NASDAQ:SUPN) Price

Supernus Pharmaceuticals: Moving Through An 'Inflection Year'

Mar 04

We Think Supernus Pharmaceuticals (NASDAQ:SUPN) Can Stay On Top Of Its Debt

May 10
We Think Supernus Pharmaceuticals (NASDAQ:SUPN) Can Stay On Top Of Its Debt

Does Supernus Pharmaceuticals (NASDAQ:SUPN) Have A Healthy Balance Sheet?

Feb 03
Does Supernus Pharmaceuticals (NASDAQ:SUPN) Have A Healthy Balance Sheet?

These 4 Measures Indicate That Supernus Pharmaceuticals (NASDAQ:SUPN) Is Using Debt Reasonably Well

Oct 19
These 4 Measures Indicate That Supernus Pharmaceuticals (NASDAQ:SUPN) Is Using Debt Reasonably Well

Supernus stock falls 12.6% after FDA declines to approve Parkinson’s disease treatment

Oct 10

Supernus Pharmaceuticals: Deep Expertise In CNS, Eyes On Qelbree Launch And Parkinson Portfolio

Aug 19

Supernus Pharmaceuticals' (NASDAQ:SUPN) Soft Earnings Are Actually Better Than They Appear

Aug 16
Supernus Pharmaceuticals' (NASDAQ:SUPN) Soft Earnings Are Actually Better Than They Appear

Supernus: A Work In Progress

Jul 29

Supernus: New Beginnings

Mar 28

Brokers Are Upgrading Their Views On Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) With These New Forecasts

Dec 02
Brokers Are Upgrading Their Views On Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) With These New Forecasts

Is Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Trading At A 34% Discount?

Nov 30
Is Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Trading At A 34% Discount?

Is Supernus Pharmaceuticals (NASDAQ:SUPN) Using Too Much Debt?

Oct 19
Is Supernus Pharmaceuticals (NASDAQ:SUPN) Using Too Much Debt?

Is Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Trading At A 49% Discount?

Aug 31
Is Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Trading At A 49% Discount?

Supernus: Well Prepared For Upcoming Challenges

Aug 26

CEO 보상 분석

Jack Khattar 의 보수는 Supernus Pharmaceuticals 의 수익과 비교하여 어떻게 변경되었나요?
날짜총 보상급여회사 수익
Jun 30 2024n/an/a

US$5m

Mar 31 2024n/an/a

-US$16m

Dec 31 2023US$13mUS$963k

US$1m

Sep 30 2023n/an/a

US$26m

Jun 30 2023n/an/a

US$43m

Mar 31 2023n/an/a

US$52m

Dec 31 2022US$10mUS$914k

US$61m

Sep 30 2022n/an/a

US$38m

Jun 30 2022n/an/a

US$57m

Mar 31 2022n/an/a

US$73m

Dec 31 2021US$8mUS$870k

US$53m

Sep 30 2021n/an/a

US$82m

Jun 30 2021n/an/a

US$100m

Mar 31 2021n/an/a

US$111m

Dec 31 2020US$7mUS$836k

US$127m

Sep 30 2020n/an/a

US$129m

Jun 30 2020n/an/a

US$118m

Mar 31 2020n/an/a

US$116m

Dec 31 2019US$8mUS$812k

US$113m

Sep 30 2019n/an/a

US$106m

Jun 30 2019n/an/a

US$105m

Mar 31 2019n/an/a

US$103m

Dec 31 2018US$7mUS$724k

US$111m

Sep 30 2018n/an/a

US$99m

Jun 30 2018n/an/a

US$87m

Mar 31 2018n/an/a

US$73m

Dec 31 2017US$6mUS$614k

US$57m

보상 대 시장: Jack 의 총 보상 ($USD 13.28M )은 US 시장( $USD 5.67M ).

보상과 수익: Jack 의 보상은 작년에 20% 이상 증가한 반면 회사 수익은 20% 이상 감소했습니다.

CEO

Jack Khattar (63 yo)

19.6yrs

테뉴어

US$13,278,093

보상

Mr. Jack A. Khattar, M.B.A., founded Supernus Pharmaceuticals, Inc. (Formerly, Shire Laboratories, Inc.) in 2005 and has served as Chief Executive Officer, President, Secretary and Director since 2005. He...

리더십 팀

이름위치테뉴어보상소유권
Jack Khattar
Founder19.6yrsUS$13.28m3.52%
$ 54.2m
Timothy Dec
Senior VP & CFO3yrsUS$2.38m0.013%
$ 201.0k
Padmanabh Bhatt
Chief Scientific Officer & Senior VP of Intellectual Property12.4yrsUS$1.47m0.016%
$ 239.5k
Frank Mottola
Senior Vice President of Quality4.6yrsUS$1.79m0.014%
$ 217.4k
Jonathan Rubin
Senior VP of Research & Development and Chief Medical Officer4.5yrsUS$1.59m0.0084%
$ 129.7k
Kevin Anderson
Compliance Officer12.6yrs데이터 없음데이터 없음
Todd Horich
Senior Vice President of Marketing9.6yrs데이터 없음데이터 없음
Taylor Raiford
Senior Vice President of Sales9.6yrs데이터 없음데이터 없음
Bryan Roecklein
Senior Vice President of Corporate Development9.1yrs데이터 없음데이터 없음
Jeff Bozick
Senior Vice President of Supply Chain3.3yrs데이터 없음데이터 없음

9.3yrs

평균 재임 기간

63yo

평균 연령

경험이 풍부한 관리: SUPN 의 관리팀은 노련하고 경험 (평균 재직 기간 9.2 년)입니다.

이사회 구성원

이름위치테뉴어보상소유권
Jack Khattar
Founder19.6yrsUS$13.28m3.52%
$ 54.2m
Charles Newhall
Independent Chairman of the Board19.6yrsUS$407.02k0.22%
$ 3.4m
Georges Gemayel
Independent Director9.4yrsUS$378.52k0.031%
$ 480.7k
Carrolee Barlow
Independent Director6.2yrsUS$376.02k0.031%
$ 480.7k
Frederick Hudson
Independent Director14.6yrsUS$385.02k0.068%
$ 1.0m

14.6yrs

평균 재임 기간

64yo

평균 연령

경험이 풍부한 이사회: SUPN 의 이사회는 노련하고 경험이 있습니다(평균 재직 기간 14.4 년).